

Dr. Dinesh S. Patel

Ph.D., CChem., FRSC (Lon.)
MANAGING DIRECTOR & CEO



TML: CS: 2013-14:

12th August, 2013.

The Vice President
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla Complex,
Bandra – East,
Mumbai- 400 051.

Dear Sir/ Madam,

Sub: Unaudited Financial results for the quarter ended 30th June, 2013.

The Board of Directors at it's meeting held today, considered and approved Unaudited Financial Results for the quarter ended 30th June, 2013 together with Limited Review Report by Statutory Auditors of the Company of the Company thereon which were earlier approved by the Audit Committee of the Company at it's meeting held before the Board Meeting.

A copy of Unaudited Financial Results for the quarter ended 30th June, 2013 is enclosed for your perusal.

This may be taken as compliance of the Listing Agreement; the Company has entered with your stock exchange.

Kindly acknowledge.

Thanking you,

Yours faithfully,

For **THEMIS MEDICARE LTD.**

DR.DINESH S.PATEL

MANAGING DIRECTOR & CEO

Themis Medicare Limited

- Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (W), Mumbai - 400 104. India
- Tel.: 91-22-2874 7184 • Fax : 2876 9183 • E-mail : dineshpatel@themismedicare.com
- Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi, Gujarat.

M. T. ANKLESHWARIA & CO.
CHARTERED ACCOUNTANTS
MADHU T. ANKLESHWARIA
B.COM. (HONS) F.C.A.

TEL: 2614 9392
7 GOKUL NIWAS,
47, BAJAJ ROAD,
VILE PARLE (WEST),
MUMBAI - 400 056.

The Board of Directors,
Themis Medicare Limited,
Mumbai.

Dear Sirs,


Re: LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS OF THEMIS MEDICARE LTD FOR THE QUARTER ENDED 30th JUNE, 2013.

1. INTRODUCTION

We have reviewed the accompanying statement of unaudited financial results of the Themis Medicare Limited, for the quarter ended on 30th June, 2013 except for the disclosures regarding public shareholding and Promoter and Promoter Group Shareholding which have been traced from disclosures made by the management but have neither been reviewed nor been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors at the meeting held on 12-08-2013. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a conclusion on these interim financial statements based on our review.

2. SCOPE OF REVIEW

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



For M.T.ANKLESHWARIA & CO,
CHARTERED ACCOUNTANTS

MADHU T. ANKLESHWARIA

PROPRIETOR

Place: Mumbai
Date: 12.08.2013


THEMIS MEDICARE LTD

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat.
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

PART I (₹ in Lakhs)

Statement of Unaudited Financial Results for the quarter ended 30th June 2013.

	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Previous year ended
		(30/06/2013)	(31/03/2013)	(30/06/2012)	(31/03/2013)
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	4,972.24	2,298.90	4,699.58	14,393.30
	(b) Other operating income	68.43	233.07	98.68	432.36
	Total income from operations (net)	5,040.67	2,531.97	4,798.26	14,825.66
2	Expenses				
	(a) Cost of materials consumed	2,215.14	1,277.19	2,583.49	7,812.36
	(b) Purchases of stock-in-trade	736.76	27.93	58.08	447.08
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(270.59)	(557.97)	223.08	(947.61)
	(d) Employee benefits expense	639.94	669.83	557.90	2,398.05
	(e) Depreciation and amortisation expense	143.12	142.60	133.82	574.61
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	1,202.61	1,029.15	1,122.07	4,196.00
	Total expenses	4,666.98	2,588.73	4,678.44	14,480.49
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	373.69	(56.76)	119.82	345.17
4	Other income	81.04	(17.74)	325.95	323.90
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	454.73	(74.50)	445.77	669.07
6	Finance costs	395.30	366.10	448.84	1,520.75
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	59.43	(440.60)	(3.07)	(851.68)
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	59.43	(440.60)	(3.07)	(851.68)
10	Tax expense	(9.72)	(9.76)	(9.15)	(39.06)
11	Net Profit / (Loss) from ordinary activities after tax (9 - 10)	69.15	(430.84)	6.08	(812.62)
12	Extraordinary items (net of tax expense Rs. NIL)	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	69.15	(430.84)	6.08	(812.62)
14	Share of profit / (loss) of associates	-	-	-	-
15	Minority interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14 +15).	69.15	(430.84)	6.08	(812.62)
17	Paid-up equity share capital- Face Value Rs. 10/- each	805.05	805.05	805.05	805.05
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				3,558.04
19	Earnings per share (before extraordinary items)				
	(a) Basic	0.86	(5.35)	0.08	(10.09)
	(b) Diluted	0.78	(4.87)	0.07	(9.18)
19ii	Earnings per share (after extraordinary items)				
	(a) Basic	0.86	(5.35)	0.08	(10.09)
	(b) Diluted	0.78	(4.87)	0.07	(9.18)




PART II

Information for the quarter ended 30/06/2013

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended	Previous year ended
		(30/06/2013)	(31/03/2013)	(30/06/2012)	(31/03/2013)
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	- Number of shares	2439685	2439685	2439685	2439685
	- Percentage of shareholding	30.30	30.30	30.30	30.30
2	Promoters and Promoter Group Shareholding				
a)	Pledged / Encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
b)	Non - encumbered				
	- Number of shares	5610815	5610815	5610815	5610815
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	69.70	69.70	69.70	69.70
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	-	-	-	-
	Received during the quarter	-	-	-	-
	Disposed of during the quarter	-	-	-	-
	Remaining unresolved at the end of the quarter	-	-	-	-

NOTES:

1. The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
2. 4 lac fully convertible preferential warrants issued to some of the promoters during the year 2012-13 will be converted into Equity Shares on 16.01.2014.
3. The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th August, 2013.



As per Review Report attached
For M. T. Ankleshwar & Co.
Chartered Accountants

Madhu T. Ankleshwar
Proprietor

Place : Mumbai
Date : 12 / 08 / 2013

By Order of the Board
For THEMIS MEDICARE LTD

Dr. DINESH PATEL
(Managing Director & CEO)